RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
DOD Biotech PCL - Stock

DOD Biotech PCL Equity 2024

DOD Biotech PCL Equity

0 THB

Ticker

DOD.BK

ISIN

TH8569010003

In 2024, DOD Biotech PCL's equity was 0 THB, a -100% increase from the 887.15 M THB equity in the previous year.

DOD Biotech PCL Aktienanalyse

What does DOD Biotech PCL do?

DOD Biotech PCL is a Thai biotechnology company specializing in the production of pharmaceuticals, diagnostics, and research products. Established in 2004, the company has become one of the most reputable biotechnology companies in Thailand. Its business model is based on the development and manufacturing of products used in medicine, veterinary medicine, and research. DOD Biotech PLC focuses on continually evolving and adapting its products to meet customer needs. Its main areas of focus are the production of pharmaceuticals, particularly anti-cancer drugs, diabetes medications, cardiovascular medications, and infection treatments. Additionally, the company manufactures diagnostics for disease early detection and precise diagnosis. It also offers a variety of products for research purposes. DOD Biotech PCL has partnerships with several companies in other countries, particularly in Asia and Europe. Its largest partner is the Indian company Sun Pharma, with which it has had a successful collaboration for many years. The company is known for its high-quality standards and is certified to ISO 9001:2015 and follows the Good Manufacturing Practices (GMP) required by the Thai FDA. DOD Biotech PCL has received international recognition, including the Frost & Sullivan Thailand Excellence Award and being recognized as a top 30 company in Thailand in 2020. Over the years, the company has built a loyal customer base that appreciates its high-quality products and excellent customer service. It has a strong online presence to better reach and serve its customers. In summary, DOD Biotech PCL is a leading biotechnology company in Thailand with a wide range of pharmaceuticals, diagnostics, and research products. It has earned an excellent reputation for its high-quality standards and top-notch customer service. With its strong online presence and partnerships with other companies in Asia and Europe, DOD Biotech PCL will undoubtedly remain an important player in the global healthcare market in the future. DOD Biotech PCL ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing DOD Biotech PCL's Equity

DOD Biotech PCL's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding DOD Biotech PCL's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating DOD Biotech PCL's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

DOD Biotech PCL's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in DOD Biotech PCL’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about DOD Biotech PCL Stock

What is the equity of DOD Biotech PCL this year?

DOD Biotech PCL has equity of 0 THB this year.

What was the equity of DOD Biotech PCL compared to the previous year?

The equity of DOD Biotech PCL has increased/decreased by -100% decreased compared to the previous year.

What impact does a high equity have on investors of DOD Biotech PCL?

A high equity is advantageous for investors of DOD Biotech PCL as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of DOD Biotech PCL?

A low equity can be a risk for investors of DOD Biotech PCL, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of DOD Biotech PCL affect the company?

An increase in equity of DOD Biotech PCL can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of DOD Biotech PCL affect the company?

A reduction in equity of DOD Biotech PCL can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of DOD Biotech PCL?

Some factors that can affect the equity of DOD Biotech PCL include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of DOD Biotech PCL so important for investors?

The equity of DOD Biotech PCL is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can DOD Biotech PCL take to change the equity?

To change equity, DOD Biotech PCL can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does DOD Biotech PCL pay?

Over the past 12 months, DOD Biotech PCL paid a dividend of 0.05 THB . This corresponds to a dividend yield of about 2.27 %. For the coming 12 months, DOD Biotech PCL is expected to pay a dividend of 0 THB.

What is the dividend yield of DOD Biotech PCL?

The current dividend yield of DOD Biotech PCL is 2.27 %.

When does DOD Biotech PCL pay dividends?

DOD Biotech PCL pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of DOD Biotech PCL?

DOD Biotech PCL paid dividends every year for the past 0 years.

What is the dividend of DOD Biotech PCL?

For the upcoming 12 months, dividends amounting to 0 THB are expected. This corresponds to a dividend yield of 0 %.

In which sector is DOD Biotech PCL located?

DOD Biotech PCL is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von DOD Biotech PCL kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DOD Biotech PCL from 5/20/2020 amounting to 0.05 THB, you needed to have the stock in your portfolio before the ex-date on 3/13/2020.

When did DOD Biotech PCL pay the last dividend?

The last dividend was paid out on 5/20/2020.

What was the dividend of DOD Biotech PCL in the year 2023?

In the year 2023, DOD Biotech PCL distributed 0 THB as dividends.

In which currency does DOD Biotech PCL pay out the dividend?

The dividends of DOD Biotech PCL are distributed in THB.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von DOD Biotech PCL

Our stock analysis for DOD Biotech PCL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DOD Biotech PCL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.